In our latest conversation on IPWatchdog Unleashed, I spoke with Brent Bellows, a partner with Knowles Intellectual Property Strategies in Atlanta, whose career sits at the intersection of hard science, patent law and pharmaceutical strategy. Brent brings an unusually integrated perspective to the life sciences patent ecosystem. He has a Ph.D. in human genetics from the University of Alabama at Birmingham, where his graduate work included researching tumor-associated antigens, and he later built a legal career that moved through prosecution, litigation, federal clerkship experience and now strategic patent portfolio work for branded pharmaceutical and biotechnology companies.

That background matters because life sciences patents are not abstract legal instruments. They are business-critical assets that often determine whether a drug candidate can attract investment, survive generic challenge and justify the enormous cost of clinical development. Brent explained that his scientific training is not some credential gathering dust on a wall. “I use my PhD and the skills I developed in graduate school at the lab bench every single day,” he said. That fluency allows him to operate where the legal and technical questions converge, particularly in the development of patent portfolios built with future ANDA and biosimilar litigation in mind.

What Judges Actually Care About in Patent Cases

One of the more interesting threads in our conversation related to Brent’s explanation of how his time clerking in the Northern District of Georgia shaped his patent practice. Having seen patent disputes from inside chambers, Brent came away with a sharper sense of what actually matters to judges. Patent lawyers often obsess over every theoretical vulnerability, but federal judges are ultimately focused on the record, the story of the invention and whether the arguments remain coherent from prosecution through litigation. Brent emphasized that the narrative embedded in the patent application itself can matter deeply, especially in pharmaceutical cases where the science, the data and the stated inventive contribution must line up.

That point led us into a discussion of issues that loom large in patent prosecution but may play out differently in court. I raised inventorship as one example: yes, getting inventorship right matters, but absent bad faith, almost every inventorship problems is fixable. Brent agreed and added inequitable conduct as another category where district judges tend to be skeptical unless the facts are truly egregious. The lesson is not that candor is optional. Quite the opposite. The lesson is that good patent practice requires judgment, discipline and credibility—particularly because the same patents may later be scrutinized by sophisticated litigators and a federal judge. The reality is that with so much to lose few games are played, so the type of egregious behavior that would lead to a finding of inequitable conduct is truly rare.

The Science Drives the Claim Construction

Claim construction also looks different in the life sciences context than it often does in high-tech litigation. Brent noted that Markman disputes are certainly important, but in many pharmaceutical and biotechnology cases, the claims are anchored tightly to the science: compositions, formulations, methods of treatment, routes of administration and FDA-approved indications. In other words, there is usually less room to stretch claim terms beyond what the molecule, method or data can support. Brent explains that the science drives the patent, and if the science fails, the patent asset rapidly loses commercial meaning.

Hatch-Waxman, ANDA Litigation and the Generic Entry Playbook

From there, our conversation moved into Hatch-Waxman, the Orange Book, ANDA litigation and the business model of generic entry. Brent walked through how a branded drug receives approval through a new drug application, how patents associated with that approved product are listed in the Orange Book, and how a generic applicant can later file an abbreviated new drug application relying on the innovator’s underlying data. With a paragraph IV certification, the generic asserts that the listed patents are asserted to be invalid, unenforceable or not infringed, triggering the familiar 45-day window for the branded company to sue. This is not merely procedural machinations. It is the architecture through which pharmaceutical exclusivity is challenged in federal court.

The economic stakes are extraordinary. Generic entry can cause severe brand erosion in a matter of months—sometimes up to 80 percent—even when the generic uses a so-called skinny label to carve out patented indications. Brent explained that the skinny label strategy may avoid certain patented uses on paper, but real-world prescribing does not always respect those boundaries. Doctors may prescribe off label, and once a generic version of the same drug is available, market substitution can and do happen fast. That dynamic is now central to ongoing debates about induced infringement, FDA labeling practices and the practical value of follow-on method-of-use patents.

The Clinical Trial Cost Problem

We also discussed the staggering cost of clinical trials and drug approval. Clinical trials in the United States can be dramatically more expensive than trials in other jurisdictions, driven by the broader cost structure of American healthcare, patient enrollment costs, site contracts, follow-up obligations and regulatory expectations. Indeed, it costs $120,000 to enroll a single patient in a U.S. based clinical trial, while in Spain the cost to enroll a single patient is less than $18,000. Brent explained that this causes many branded pharmaceutical and biotechnology companies to look to jurisdictions such as Eastern Europe, Spain, Portugal, and China because clinical trial costs can be substantially lower. The broader takeaway is that U.S. drug prices cannot be understood without accounting for the enormous front-end cost of proving safety and efficacy, particularly when clinical development increasingly requires large, statistically meaningful trials across diverse populations.

The Economics of Failure Behind Drug Pricing

Sadly, the public often sees only the launch price of a new drug, not the years of failed candidates, abandoned trials, regulatory compliance, manufacturing controls and capital risk that preceded approval. “As a consumer, you want to pay less. As a creator, you want to charge more,” I said. That is not a moral indictment; it is the operating reality of markets. Brent underscored that oncology is an especially brutal example. Failure rates are enormous, and promising Phase II data can collapse in Phase III when tested across a broader, more heterogeneous patient population. The public discussion around drug pricing rarely accounts for the economics of failure. One successful drug must carry the weight of many unsuccessful ones. That reality does not make every pricing decision defensible, but it does make simplistic attacks on patents and exclusivity dangerously naïve to the point of being extremely misleading.

Do We Want Breakthrough Therapies—or Just Cheaper Copies?

The core policy question is whether we want more breakthrough therapies or merely cheaper access to therapies already invented. Those are not the same objective. As I explained, if policymakers keep compressing exclusivity windows and accelerating generic entry, innovators will have to recover investment over shorter periods. That means higher launch prices, fewer risky projects, or both. It also means capital will flow toward safer singles and doubles rather than the grand-slam therapies society claims to want: cures for cancer, Alzheimer’s, Parkinson’s, antibiotic resistance and other hard problems.

Brent put the point bluntly: “the system does work. You do get generics.” That is the part critics too often ignore. Patents do not block generics forever—and often do not block generics for more than five (5) years. Patents and data exclusivity create a temporary commercial runway that makes the initial investment rational. After that, society receives the long-term benefit of genericized medicines. The Hatch-Waxman framework, imperfect as it is, was designed around that tradeoff: incentivize innovation first, then enable generic competition later.

The policy danger today is that we are increasingly punishing success. Brent highlighted the Inflation Reduction Act’s drug negotiation framework as an example of a perverse incentive structure. The drugs targeted for negotiation are often those addressing the most pressing and expensive health problems in America: cancer, diabetes, kidney disease and cardiovascular conditions. If a company develops a drug that meaningfully reduces downstream healthcare costs, why should the policy response be to penalize the very success we should want more of? That is a broader innovation-policy failure.

The Cost of the Cure That Never Exists

We also talked about drug prices in isolation while ignoring the cost of nonexistence. What is the price of a therapy never developed? What is the cost of a cure that investors declined to fund because the reward horizon was too uncertain? Brent captured the point perfectly when he said, “without patents, you’re not even getting these drugs developed.” That is not rhetoric. It is the foundation of private-sector biomedical innovation.

The conversation closed where serious patent policy should begin: with incentives. Scientists and physicians may be driven by the desire to help patients, but drug development requires capital, and capital requires a credible return. Patents are not a windfall. They are the mechanism that allows fragile scientific possibility to become a funded development program, then a regulated product, then eventually a generic medicine. Or, as Brent said in one of the simplest and most accurate lines of the episode: “drugs don’t fall off of trees.”

More IPWatchdog Unleashed

You can listen to the entire podcast episode by downloading it wherever you normally access podcasts or by visiting IPWatchdog Unleashed on Buzzsprout. You can also listen to IPWatchdog Unleashed conversations on the IPWatchdog YouTube channel. For more IPWatchdog Unleashed, see below for our growing archive of previous episodes.